Cargando…
Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998–2020)
BACKGROUND: Malaria remains highly endemic in Cameroon. The rapid emergence and spread of drug resistance was responsible for the change from monotherapies to artemisinin-based combinations. This systematic review and meta-analysis aimed to determine the prevalence and distribution of Plasmodium fal...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796563/ https://www.ncbi.nlm.nih.gov/pubmed/33422080 http://dx.doi.org/10.1186/s12936-020-03543-8 |
_version_ | 1783634709961506816 |
---|---|
author | Niba, Peter Thelma Ngwa Nji, Akindeh M. Evehe, Marie-Solange Ali, Innocent M. Netongo, Palmer Masumbe Ngwafor, Randolph Moyeh, Marcel N. Ngum, Lesley Ngum Ndum, Oliva Ebie Acho, Fon Abongwa Mbu’u, Cyrille Mbanwi Fosah, Dorothy A. Atogho-Tiedeu, Barbara Achonduh-Atijegbe, Olivia Djokam-Dadjeu, Rosine Chedjou, Jean Paul Kengne Bigoga, Jude D. Moukoko, Carole Else Eboumbou Ajua, Anthony Achidi, Eric Tallah, Esther Leke, Rose G. F. Tourgordi, Alexis Ringwald, Pascal Alifrangis, Michael Mbacham, Wilfred F. |
author_facet | Niba, Peter Thelma Ngwa Nji, Akindeh M. Evehe, Marie-Solange Ali, Innocent M. Netongo, Palmer Masumbe Ngwafor, Randolph Moyeh, Marcel N. Ngum, Lesley Ngum Ndum, Oliva Ebie Acho, Fon Abongwa Mbu’u, Cyrille Mbanwi Fosah, Dorothy A. Atogho-Tiedeu, Barbara Achonduh-Atijegbe, Olivia Djokam-Dadjeu, Rosine Chedjou, Jean Paul Kengne Bigoga, Jude D. Moukoko, Carole Else Eboumbou Ajua, Anthony Achidi, Eric Tallah, Esther Leke, Rose G. F. Tourgordi, Alexis Ringwald, Pascal Alifrangis, Michael Mbacham, Wilfred F. |
author_sort | Niba, Peter Thelma Ngwa |
collection | PubMed |
description | BACKGROUND: Malaria remains highly endemic in Cameroon. The rapid emergence and spread of drug resistance was responsible for the change from monotherapies to artemisinin-based combinations. This systematic review and meta-analysis aimed to determine the prevalence and distribution of Plasmodium falciparum drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon from January 1998 to August 2020. METHODS: The PRISMA-P and PRISMA statements were adopted in the inclusion of studies on single nucleotide polymorphisms (SNPs) of P. falciparum anti-malarial drug resistance genes (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, Pfatp6, Pfcytb and Pfk13). The heterogeneity of the included studies was evaluated using the Cochran’s Q and I(2) statistics. The random effects model was used as standard in the determination of heterogeneity between studies. RESULTS: Out of the 902 records screened, 48 studies were included in this aggregated meta-analysis of molecular data. A total of 18,706 SNPs of the anti-malarial drug resistance genes were genotyped from 47,382 samples which yielded a pooled prevalence of 35.4% (95% CI 29.1–42.3%). Between 1998 and 2020, there was significant decline (P < 0.0001 for all) in key mutants including Pfcrt 76 T (79.9%-43.0%), Pfmdr1 86Y (82.7%-30.5%), Pfdhfr 51I (72.2%-66.9%), Pfdhfr 59R (76.5%-67.8%), Pfdhfr 108 N (80.8%-67.6%). The only exception was Pfdhps 437G which increased over time (30.4%-46.9%, P < 0.0001) and Pfdhps 540E that remained largely unchanged (0.0%-0.4%, P = 0.201). Exploring mutant haplotypes, the study observed a significant increase in the prevalence of Pfcrt CVIET mixed quintuple haplotype from 57.1% in 1998 to 57.9% in 2020 (P < 0.0001). In addition, within the same study period, there was no significant change in the triple Pfdhfr IRN mutant haplotype (66.2% to 67.3%, P = 0.427). The Pfk13 amino acid polymorphisms associated with artemisinin resistance were not detected. CONCLUSIONS: This review reported an overall decline in the prevalence of P. falciparum gene mutations conferring resistance to 4-aminoquinolines and amino alcohols for a period over two decades. Resistance to artemisinins measured by the presence of SNPs in the Pfk13 gene does not seem to be a problem in Cameroon. Systematic review registration PROSPERO CRD42020162620 |
format | Online Article Text |
id | pubmed-7796563 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77965632021-01-11 Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998–2020) Niba, Peter Thelma Ngwa Nji, Akindeh M. Evehe, Marie-Solange Ali, Innocent M. Netongo, Palmer Masumbe Ngwafor, Randolph Moyeh, Marcel N. Ngum, Lesley Ngum Ndum, Oliva Ebie Acho, Fon Abongwa Mbu’u, Cyrille Mbanwi Fosah, Dorothy A. Atogho-Tiedeu, Barbara Achonduh-Atijegbe, Olivia Djokam-Dadjeu, Rosine Chedjou, Jean Paul Kengne Bigoga, Jude D. Moukoko, Carole Else Eboumbou Ajua, Anthony Achidi, Eric Tallah, Esther Leke, Rose G. F. Tourgordi, Alexis Ringwald, Pascal Alifrangis, Michael Mbacham, Wilfred F. Malar J Research BACKGROUND: Malaria remains highly endemic in Cameroon. The rapid emergence and spread of drug resistance was responsible for the change from monotherapies to artemisinin-based combinations. This systematic review and meta-analysis aimed to determine the prevalence and distribution of Plasmodium falciparum drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon from January 1998 to August 2020. METHODS: The PRISMA-P and PRISMA statements were adopted in the inclusion of studies on single nucleotide polymorphisms (SNPs) of P. falciparum anti-malarial drug resistance genes (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, Pfatp6, Pfcytb and Pfk13). The heterogeneity of the included studies was evaluated using the Cochran’s Q and I(2) statistics. The random effects model was used as standard in the determination of heterogeneity between studies. RESULTS: Out of the 902 records screened, 48 studies were included in this aggregated meta-analysis of molecular data. A total of 18,706 SNPs of the anti-malarial drug resistance genes were genotyped from 47,382 samples which yielded a pooled prevalence of 35.4% (95% CI 29.1–42.3%). Between 1998 and 2020, there was significant decline (P < 0.0001 for all) in key mutants including Pfcrt 76 T (79.9%-43.0%), Pfmdr1 86Y (82.7%-30.5%), Pfdhfr 51I (72.2%-66.9%), Pfdhfr 59R (76.5%-67.8%), Pfdhfr 108 N (80.8%-67.6%). The only exception was Pfdhps 437G which increased over time (30.4%-46.9%, P < 0.0001) and Pfdhps 540E that remained largely unchanged (0.0%-0.4%, P = 0.201). Exploring mutant haplotypes, the study observed a significant increase in the prevalence of Pfcrt CVIET mixed quintuple haplotype from 57.1% in 1998 to 57.9% in 2020 (P < 0.0001). In addition, within the same study period, there was no significant change in the triple Pfdhfr IRN mutant haplotype (66.2% to 67.3%, P = 0.427). The Pfk13 amino acid polymorphisms associated with artemisinin resistance were not detected. CONCLUSIONS: This review reported an overall decline in the prevalence of P. falciparum gene mutations conferring resistance to 4-aminoquinolines and amino alcohols for a period over two decades. Resistance to artemisinins measured by the presence of SNPs in the Pfk13 gene does not seem to be a problem in Cameroon. Systematic review registration PROSPERO CRD42020162620 BioMed Central 2021-01-09 /pmc/articles/PMC7796563/ /pubmed/33422080 http://dx.doi.org/10.1186/s12936-020-03543-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Niba, Peter Thelma Ngwa Nji, Akindeh M. Evehe, Marie-Solange Ali, Innocent M. Netongo, Palmer Masumbe Ngwafor, Randolph Moyeh, Marcel N. Ngum, Lesley Ngum Ndum, Oliva Ebie Acho, Fon Abongwa Mbu’u, Cyrille Mbanwi Fosah, Dorothy A. Atogho-Tiedeu, Barbara Achonduh-Atijegbe, Olivia Djokam-Dadjeu, Rosine Chedjou, Jean Paul Kengne Bigoga, Jude D. Moukoko, Carole Else Eboumbou Ajua, Anthony Achidi, Eric Tallah, Esther Leke, Rose G. F. Tourgordi, Alexis Ringwald, Pascal Alifrangis, Michael Mbacham, Wilfred F. Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998–2020) |
title | Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998–2020) |
title_full | Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998–2020) |
title_fullStr | Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998–2020) |
title_full_unstemmed | Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998–2020) |
title_short | Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998–2020) |
title_sort | drug resistance markers within an evolving efficacy of anti-malarial drugs in cameroon: a systematic review and meta-analysis (1998–2020) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7796563/ https://www.ncbi.nlm.nih.gov/pubmed/33422080 http://dx.doi.org/10.1186/s12936-020-03543-8 |
work_keys_str_mv | AT nibapeterthelmangwa drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT njiakindehm drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT evehemariesolange drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT aliinnocentm drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT netongopalmermasumbe drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT ngwaforrandolph drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT moyehmarceln drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT ngumlesleyngum drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT ndumolivaebie drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT achofonabongwa drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT mbuucyrillembanwi drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT fosahdorothya drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT atoghotiedeubarbara drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT achonduhatijegbeolivia drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT djokamdadjeurosine drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT chedjoujeanpaulkengne drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT bigogajuded drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT moukokocaroleelseeboumbou drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT ajuaanthony drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT achidieric drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT tallahesther drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT lekerosegf drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT tourgordialexis drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT ringwaldpascal drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT alifrangismichael drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 AT mbachamwilfredf drugresistancemarkerswithinanevolvingefficacyofantimalarialdrugsincameroonasystematicreviewandmetaanalysis19982020 |